comprehensive -WSS

comprehensive

author：entertainment 2025-10-02 19:38:49 - browse：79783

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Eli Lilly’s Zepbound improved liver scarring in mid

hotspot

focus

WSS

Patients, doctors press FTC to beef up hospital merger scrutiny

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Covid’s new normal has set in amid another rise in cases

Elevance PBM president out as customers face prescription chaos

Akili changes sales model for its ADHD video game treatment

A new initiative will help leaders fight the next pandemic

explore

comprehensive

leisure time

Supreme Court strikes down use of affirmative action

Transgender sports debate: Physicians say bans are health issue

In age of alternative facts, a scholarly course on calling out crap

Finland to offer bird flu vaccine to select groups of people, a possible global first

Novavax promises a turnaround & Lilly roils the obesity market

A new initiative will help leaders fight the next pandemic

Psychedelics group wrestles with new pharma identity

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

In Memoriam: Notable people who died in 2023

Data don't support strong claims for Covid

Wikipedia

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

The most pressing bird flu mysteries scientists want answered

Eli Lilly’s Zepbound improved liver scarring in mid

BD to buy Edwards patient monitoring unit for $4.2 billion

Covid’s new normal has set in amid another rise in cases

Midwives could help bridge maternal health disparities in the U.S.

hotspot

knowledge

focus

focus